双侧乳腺er+的乳腺癌kras突变跟 fgfr1基因扩增对激素治疗的不同反应.pdfVIP

GeneDiagnostic,ZytoVision NIH Public Access Author Manuscript Mol Cancer Ther. Author manuscript; available in PMC 2013 June 14. N Published in final edited form as: I H Mol Cancer Ther. 2012 October ; 11(10): 2301–2305. doi:10.1158/1535-7163.MCT-12-0511. - P A A u Discordant cellular response to pre-surgical letrozole in bilateral t h o synchronous ER+ breast cancers with a KRAS mutation or r M a FGFR1 gene amplification n u s 1 1,5 4,5 2,5 c Justin M. Balko , Ingrid A. Mayer , Melinda E. Sanders , Todd W. Miller , Maria G. r i 4 3,5 6,7,8,9 7,8,9 p Kuba , Ingrid M. Meszoely , Nikhil Wagle , Levi A. Garraway , and Carlos L. t Arteaga1,2,5 1Department of Medicine, Vanderbilt-Ingram Cancer Center; Vanderbilt University, Nashville, TN 37232 2Department of Cancer Biology, Vanderbilt-Ingram Cancer Center; Vanderbilt University, Nashville, TN 37232 N 3Department of Surgery, Vanderbilt-Ingram Cancer Center; Vanderbilt University, Nashville, TN I H 37232 - P A 4 Department of Pathology, Vanderbilt-Ingram Cancer Center; Vanderbilt University, Nashville, TN A 37232 u t h 5Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center; Vanderbilt University, o r Nashville, TN 37232 M a 6Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA n u 02115 s c